Residue 146 regulates prolactin receptor folding, basal activity and ligand-responsiveness: Potential implications in breast tumorigenesis

被引:10
作者
Zhang, Chi [1 ,2 ]
Cherifi, Ibtissem [1 ,2 ]
Nygaard, Mads [3 ]
Haxholm, Gitte W. [3 ]
Bogorad, Roman L. [1 ,2 ]
Bernadet, Marie [1 ,2 ]
England, Patrick [4 ]
Broutin, Isabelle [5 ]
Kragelund, Birthe B. [3 ]
Guidotti, Jacques-Emmanuel [1 ,2 ]
Goffin, Vincent [1 ,2 ]
机构
[1] INSERM, INEM, Equipe Physiopathol Hormones PRL GH, U1151, F-75993 Paris 14, France
[2] Univ Paris 05, Sorbonne Paris Cite, Paris, France
[3] Univ Copenhagen, Dept Biol, Struct Biol & NMR Lab, Copenhagen, Denmark
[4] Inst Pasteur, Dept Biol Struct & Chim, F-75015 Paris, France
[5] CNRS, UMR 8015, Lab Cristallog & RMN Biol, F-8015 Paris, France
关键词
STAT5; MAPK; Proliferation; Ile146; Structure; Breast cancer; GROWTH-HORMONE RECEPTOR; COMMON BETA-SUBUNIT; HUMAN PRL RECEPTORS; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; EXTRACELLULAR DOMAIN; CYTOKINE RECEPTORS; INHIBITORY-ACTION; CRYSTAL-STRUCTURE; GENETIC-VARIATION;
D O I
10.1016/j.mce.2014.12.006
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
PRLRI146L is the first identified gain-of-function variant of the prolactin receptor (PRLR) that was proposed to be associated with benign breast tumorigenesis. Structural investigations suggested this hydrophobic core position in the extracellular D2 domain to be linked to receptor dimerization. Here, we used a mutational approach to address how the conservative I-to-L substitution induced constitutive activity. Using cell-based assays of different I146-PRLR variants in combination with spectroscopic/nuclear magnetic resonance analyses we found that chemical manipulation of position 146 profoundly altered folding, PRL-responsiveness, and ligand-independent activity of the receptor in a mutation-specific manner. Together, these data further add to the critical role of position 146, showing it to also be crucial to structural integrity thereby imposing on the biological PRLR properties. When stably introduced in MCF-7 (luminal) and MDA-MB231 (mesenchymal) breast cancer cells, the most potent of the PRL-insensitive mutants (PRLRI146D) had minimal impact on cell proliferation and cell differentiation status. (c) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:173 / 188
页数:16
相关论文
共 73 条
  • [1] Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways
    Acosta, JJ
    Muñoz, RM
    González, L
    Subtil-Rodríguez, A
    Domínguez-Cáceres, MA
    García-Martínez, JM
    Calcabrini, A
    Lazaro-Trueba, I
    Martín-Pérez, J
    [J]. MOLECULAR ENDOCRINOLOGY, 2003, 17 (11) : 2268 - 2282
  • [2] Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells
    Aksamitiene, Edita
    Achanta, Sirisha
    Kolch, Walter
    Kholodenko, Boris N.
    Hoek, Jan B.
    Kiyatkin, Anatoly
    [J]. CELLULAR SIGNALLING, 2011, 23 (11) : 1794 - 1805
  • [4] Development of pure prolactin receptor antagonists
    Bernichtein, S
    Kayser, C
    Dillner, K
    Moulin, S
    Kopchick, JJ
    Martial, JA
    Norstedt, G
    Isaksson, O
    Kelly, PA
    Goffin, V
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (38) : 35988 - 35999
  • [5] New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity
    Bernichtein, S
    Jeay, S
    Vaudry, R
    Kelly, PA
    Goffin, V
    [J]. ENDOCRINE, 2003, 20 (1-2) : 177 - 189
  • [6] Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign
    Binder, Christina
    Lafayette, Amy
    Archibeque, Ivonne
    Sun, Yu
    Plewa, Cherylene
    Sinclair, Angus
    Emkey, Renee
    [J]. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2008, 6 (01) : 27 - 37
  • [7] BISWAS R, 1987, CANCER RES, V47, P3509
  • [8] Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors
    Bogorad, Roman L.
    Courtillot, Carine
    Mestayer, Chidi
    Bernichtein, Sophie
    Harutyunyan, Lilya
    Jomain, Jean-Baptiste
    Bachelot, Anne
    Kuttenn, Frederique
    Kelly, Paul A.
    Goffin, Vincent
    Touraine, Philippe
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (38) : 14533 - 14538
  • [9] Molecular phylogeny within type I cytokines and their cognate receptors
    Boulay, JL
    O'Shea, JJ
    Paul, WE
    [J]. IMMUNITY, 2003, 19 (02) : 159 - 163
  • [10] Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
    Brooks, Andrew J.
    Dai, Wei
    O'Mara, Megan L.
    Abankwa, Daniel
    Chhabra, Yash
    Pelekanos, Rebecca A.
    Gardon, Olivier
    Tunny, Kathryn A.
    Blucher, Kristopher M.
    Morton, Craig J.
    Parker, Michael W.
    Sierecki, Emma
    Gambin, Yann
    Gomez, Guillermo A.
    Alexandrov, Kirill
    Wilson, Ian A.
    Doxastakis, Manolis
    Mark, Alan E.
    Waters, Michael J.
    [J]. SCIENCE, 2014, 344 (6185) : 710 - +